Organogenesis (ORGO) – Analysts’ Weekly Ratings Updates

Organogenesis (NASDAQ: ORGO) has recently received a number of price target changes and ratings updates:

• 11/20/2025 – Organogenesis had its price target raised by analysts at BTIG Research from $7.00 to $9.00. They now have a “buy” rating on the stock.
• 11/19/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Organogenesis was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.
• 10/8/2025 – Organogenesis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Organogenesis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Organogenesis had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.